Deciphera Pharmaceuticals LLC Performance
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
The firm shows a Beta (market volatility) of 0.2, which means not very significant fluctuations relative to the market. As returns on the market increase, Deciphera Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Deciphera Pharmaceuticals is expected to be smaller as well. Deciphera Pharmaceuticals right now shows a risk of 0.0%. Please confirm Deciphera Pharmaceuticals jensen alpha, accumulation distribution, relative strength index, as well as the relationship between the value at risk and day typical price , to decide if Deciphera Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Deciphera Pharmaceuticals LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Deciphera Pharmaceuticals is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 64.7 M |
Deciphera |
Deciphera Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,332 in Deciphera Pharmaceuticals LLC on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Deciphera Pharmaceuticals LLC or generate 0.0% return on investment over 90 days. Deciphera Pharmaceuticals LLC is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Deciphera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Deciphera Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Deciphera Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Deciphera Pharmaceuticals LLC, and traders can use it to determine the average amount a Deciphera Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| DCPH |
Based on monthly moving average Deciphera Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Deciphera Pharmaceuticals by adding Deciphera Pharmaceuticals to a well-diversified portfolio.
Deciphera Pharmaceuticals Fundamentals Growth
Deciphera Stock prices reflect investors' perceptions of the future prospects and financial health of Deciphera Pharmaceuticals, and Deciphera Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Deciphera Stock performance.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Price To Earning | (6.78) X | |||
| Price To Book | 7.00 X | |||
| Price To Sales | 12.65 X | |||
| Revenue | 163.36 M | |||
| EBITDA | (210.96 M) | |||
| Cash And Equivalents | 383.85 M | |||
| Cash Per Share | 5.74 X | |||
| Total Debt | 25.88 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (146.7 M) | |||
| Earnings Per Share | (2.21) X | |||
| Total Asset | 473.57 M | |||
| Retained Earnings | (1.43 B) | |||
| Current Asset | 70.55 M | |||
| Current Liabilities | 5.98 M | |||
About Deciphera Pharmaceuticals Performance
By evaluating Deciphera Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Deciphera Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Deciphera Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Deciphera Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 280 people.Things to note about Deciphera Pharmaceuticals performance evaluation
Checking the ongoing alerts about Deciphera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Deciphera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Deciphera Pharmaceuticals is not yet fully synchronised with the market data | |
| Deciphera Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 163.36 M. Net Loss for the year was (194.94 M) with loss before overhead, payroll, taxes, and interest of (62.55 M). | |
| Deciphera Pharmaceuticals LLC currently holds about 383.85 M in cash with (146.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Deciphera Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Deciphera Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Deciphera Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Deciphera Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Deciphera Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Deciphera Pharmaceuticals' stock. These opinions can provide insight into Deciphera Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |